Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 5/20 | 0.80 |
| ▸ | MAPT | P10636 | 4/20 | 0.80 |
| ▸ | ABCC4 | O15439 | 4/20 | 0.80 |
| ▸ | ABCC2 | Q92887 | 4/20 | 0.80 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.80 |
| ▸ | GAA | P10253 | 3/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.80 |
| ▸ | ABCC3 | O15438 | 3/20 | 0.80 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.80 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.80 |
| ▸ | SLCO2B1 | O94956 | 2/20 | 0.80 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.80 |
| ▸ | SLCO1A2 | P46721 | 2/20 | 0.80 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.80 |
| ▸ | SLCO1B1 | Q9Y6L6 | 2/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.80 |
| ▸ | MEN1 | O00255 | 2/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.80 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14356353 | 1.00 | ABCB11 (0.80) | ABCB11MAPTABCC4ABCC2TBXA2R | |
| SCHEMBL30063061 | 1.00 | ABCB11 (0.80) | ABCB11MAPTABCC4ABCC2TBXA2R | |
| SCHEMBL29534651 | 1.00 | ABCB11 (0.80) | ABCB11MAPTABCC4ABCC2TBXA2R | |
| SCHEMBL14252218 | 0.94 | ABCB11 (0.79) | ABCB11MAPTABCC4ABCC2TBXA2R | |
| SCHEMBL23541658 | 0.93 | ABCB11 (0.83) | ABCB11MAPTABCC4ABCC2TBXA2R | |
| SCHEMBL23541652 | 0.93 | MAPT (0.83) | ABCB11MAPTABCC4ABCC2TBXA2R | |
| SCHEMBL23594215 | 0.93 | ABCB11 (0.83) | ABCB11MAPTABCC4ABCC2TBXA2R | |
| SCHEMBL29559659 | 0.93 | ABCB11 (0.83) | ABCB11MAPTABCC4ABCC2TBXA2R | |
| SCHEMBL23510705 | 0.93 | MAPT (0.83) | ABCB11MAPTABCC4ABCC2TBXA2R | |
| SCHEMBL31447566 | 0.93 | ABCB11 (0.83) | ABCB11MAPTABCC4ABCC2TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11224599-B2 | Therapeutic agents and methods | POP TEST ONCOLOGY LLC | 2022-01-18 | — | — | US | disclosed |
| US-20210353623-A1 | THERAPEUTIC AGENTS AND METHODS | POP TEST ONCOLOGY LLC | 2021-11-18 | — | — | US | disclosed |
| US-11040037-B2 | Therapeutic agents and methods | POP TEST ONCOLOGY LLC | 2021-06-22 | — | — | US | disclosed |
| US-8404664-B2 | Phosphonated Rifamycins and uses thereof for the prevention and treatment of bone and joint infections | TARGANTA THERAPEUTICS, INC. (CA) | 2013-03-26 | — | — | US | disclosed |
| US-20100152267-A1 | NOVEL RIFAMYCIN 3,4-(3-SUBSTITUTED AMINOMETHYL) FUSED PYRROLO DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2010-06-17 | — | — | US | disclosed |
| US-20100152267-A1 | NOVEL RIFAMYCIN 3,4-(3-SUBSTITUTED AMINOMETHYL) FUSED PYRROLO DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2010-06-17 | — | — | US | disclosed |
| US-7678791-B2 | Nitroheteroaryl-containing rifamycin derivatives | CUMBRE IP VENTURES, L.P. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20080139577-A1 | Nitroheteroaryl-containing rifamycin derivatives | CUMBRE PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2007096703-A2 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | TARGANTA THERAPEUTICS INC. (CA) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11224599-B2 | Therapeutic agents and methods | NR1H4, NR3C1, NR3C2 | ABCB11 715/4885MAPT 4807/4885ABCC4 3201/4885 |
| US-20210353623-A1 | THERAPEUTIC AGENTS AND METHODS | NR1H4, NR3C1, NR3C2 | ABCB11 715/4885MAPT 4807/4885ABCC4 3201/4885 |
| US-20080139577-A1 | Nitroheteroaryl-containing rifamycin derivatives | NRDC, FNTB, RIF1 | ABCB11 266/4885MAPT 2006/4885ABCC4 907/4885 |
| US-11040037-B2 | Therapeutic agents and methods | NR1H4, NR3C1, NR3C2 | ABCB11 715/4885MAPT 4807/4885ABCC4 3201/4885 |
| US-20100152267-A1 | NOVEL RIFAMYCIN 3,4-(3-SUBSTITUTED AMINOMETHYL) FUSED PYRROLO DERIVATIVES | RIF1, Q6ZSR9, RPS6KA5 | ABCB11 1039/4885MAPT 2246/4885ABCC4 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.